0000950170-24-025982.txt : 20240305
0000950170-24-025982.hdr.sgml : 20240305
20240305162146
ACCESSION NUMBER: 0000950170-24-025982
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240303
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daniell Richard
CENTRAL INDEX KEY: 0001726096
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 24720785
MAIL ADDRESS:
STREET 1: 5 BASEL STREET, PO BOX 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
BUSINESS PHONE: 972 (3) 914-8213
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 124 DVORA HANEVI'A ST.
CITY: TEL AVIV
STATE: L3
ZIP: 6944020
4
1
ownership.xml
4
X0508
4
2024-03-03
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001726096
Daniell Richard
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
124 DVORA HANEVI'A ST.,
TEL AVIV
L3
6944020
ISRAEL
false
true
false
false
Exec. VP, European Commercial
true
Ordinary Shares
2024-03-03
4
M
false
62250
A
132020
D
Ordinary Shares
2024-03-04
4
S
false
62250
13.3373
D
69770
D
Ordinary Shares
2024-03-04
4
M
false
33512
A
103282
D
Ordinary Shares
2024-03-04
4
S
false
33512
13.3373
D
69770
D
Restricted Share Units
2024-03-03
4
M
false
62250
0
D
Ordinary Shares
62250
186753
D
Restricted Share Units
2024-03-04
4
M
false
33512
0
D
Ordinary Shares
33512
67024
D
Restricted Share Units
2024-03-04
4
A
false
81845
0
A
Ordinary Shares
81845
81845
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2023.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.445, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
Restricted share units were granted on March 3, 2023, with 62,250 vesting on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 62,253 vesting on March 3, 2027.
Restricted share units were granted on March 4, 2022, with 33,512 vested on March 4, 2023 and March 4, 2024, and 33,512 vesting on each of March 4, 2025 and March 4, 2026.
Restricted share units were granted on March 4, 2024, with 20,461 vesting on each of March 4, 2025, March 4, 2026 and March 4, 2027, and 20,462 vesting on March 4, 2028.
/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell
2024-03-05